```json
{
"ranked_hypotheses": [
{
"title": "Therapeutic Window Exists Because Amplified Signals (Not Baseline) Drive Pathogenesis (H3)",
"description": "G2019S basal RAB10 phosphorylation elevation may be secondary; true pathogenic driver is amplified stress-response signaling. Partial LRRK2 inhibition sufficient to normalize stress-induced spikes while preserving necessary baseline functions. LRRK2 knockout mice viability supports non-essential baseline hypothesis. Age-dependent neurodegeneration in knock-in mice suggests stress-dependent pathology rather than chronic baseline elevation.",
"target_gene": "LRRK2",
"dimension_scores": {
"evidence_strength": 0.78,
"novelty": 0.55,
"feasibility": 0.88,
"therapeutic_potential": 0.92,
"mechanistic_plausibility": 0.74,
"druggability": 0.88,
"safety_profile": 0.75,
"competitive_landscape": 0.72,
"data_availability": 0.82,
"reproducibility": 0.75
},
"composite_score": 0.78,
"evidence_for": [
{"claim": "LRRK2 knockout mice are viable, suggesting baseline function is non-essential", "pmid": "18687812"},
{"claim": "G2019S knock-in mice show age-dependent neurodegeneration only under stress", "pmid": "31694915"},
{"claim": "LRRK2 kinase inhibitors protect models at sub-maximal doses", "pmid": "33106311"}
],
"evidence_against": [
{"claim": "Lung foamy macrophage findings suggest safety may require complete inhibition", "pmid": "35241464"},
{"claim": "Age-dependent phenotype does not prove stress-dependence", "pmid": "31694915"}
]
},
{
"title": "G2019S Acts as Lysosomal Volume-Sensing Amplifier via Enhanced RAB29-Dependent Recruitment (H1)",
"description": "G2019S specifically hyperactivates LRRK2 when recruited to swelling lysosomes via RAB29, creating pathogenic positive feedback where membrane stress increases RAB10 phosphorylation more than wild-type. Key experimental prediction: rise kinetics (slope) should differ between G2019S and WT, not merely baseline offset. RAB29 pathogenic mutations (PARK23) confirm disease relevance of this axis.",
"target_gene": "LRRK2,RAB29",
"dimension_scores": {
"evidence_strength": 0.72,
"novelty": 0.78,
"feasibility": 0.82,
"therapeutic_potential": 0.85,
"mechanistic_plausibility": 0.68,
"druggability": 0.70,
"safety_profile": 0.72,
"competitive_landscape": 0.65,
"data_availability": 0.68,
"reproducibility": 0.70
},
"composite_score": 0.73,
"evidence_for": [
{"claim": "RAB29 pathogenic mutations (PARK23) cause early-onset Parkinsonism", "pmid": "28165311"},
{"claim": "RAB29 recruits LRRK2 to stressed lysosomes via GTP-dependent mechanism", "pmid": "30635564"},
{"claim": "G2019S shows selectively elevated RAB10 phosphorylation at lysosomes", "pmid": "33448356"}
],
"evidence_against": [
{"claim": "Recruitment enhancement of G2019S relative to WT not directly demonstrated", "pmid": "31511666"},
{"claim": "Positive feedback loop mechanism not shown", "pmid": "30635564"}
]
},
{
"title": "RAB29 Is the Critical Molecular Switch That Determines Whether LRRK2 Signal Amplification Occurs (H4)",
"description": "RAB29 functions as a gatekeeper—when lysosomes swell, RAB29-GTP increases, recruits LRRK2, and G2019S hyperphosphorylates RAB10 disproportionately. The amplification is RAB29-dependent. Strategic pivot: RAB29 serves as predictive biomarker rather than drug target. RAB29 knockout in G2019S patient-derived neurons would determine if amplification requires RAB29.",
"target_gene": "RAB29",
"dimension_scores": {
"evidence_strength": 0.70,
"novelty": 0.82,
"feasibility": 0.78,
"therapeutic_potential": 0.80,
"mechanistic_plausibility": 0.72,
"druggability": 0.52,
"safety_profile": 0.78,
"competitive_landscape": 0.72,
"data_availability": 0.62,
"reproducibility": 0.68
},
"composite_score": 0.71,
"evidence_for": [
{"claim": "RAB29 localizes to swollen lysosomes", "pmid": "30635564"},
{"claim": "RAB29 activates LRRK2 in cells", "pmid": "28067317"},
{"claim": "RAB29 knockout rescues LRRK2 pathogenic phenotypes in zebrafish", "pmid": "31743699"}
],
"evidence_against": [
{"claim": "Zebrafish data may not translate to mammalian neurons", "pmid": "31743699"},
{"claim": "RAB29 mutations cause disease through LRRK2 activation—switch model unclear", "pmid": "28165311"}
]
},
{
"title": "LRRK2 G2019S Uncouples RAB29-Dependent Spatial Control from Kinase Activity (H7)",
"description": "Normally RAB29 recruits LRRK2 specifically to stressed lysosomes for localized RAB10 phosphorylation. G2019S increases kinase activity even in cytosolic/untargeted LRRK2, creating diffuse RAB10 phosphorylation that disrupts normal endosomal trafficking. RAB29 overexpression rescuing G2019S phenotypes suggests spatial control not completely uncoupled.",
"target_gene": "LRRK2,RAB29",
"dimension_scores": {
"evidence_strength": 0.62,
"novelty": 0.85,
"feasibility": 0.58,
"therapeutic_potential": 0.68,
"mechanistic_plausibility": 0.65,
"druggability": 0.45,
"safety_profile": 0.62,
"competitive_landscape": 0.78,
"data_availability": 0.55,
"reproducibility": 0.62
},
"composite_score": 0.64,
"evidence_for": [
{"claim": "LRRK2:RAB29 cryo-EM structure shows specific binding interface", "pmid": "34519112"},
{"claim": "RAB29 overexpression rescues G2019S phenotypes", "pmid": "30635564"}
],
"evidence_against": [
{"claim": "R1078 is in WD40 domain, not RAB29 interface—mutation may confound results", "pmid": "34519112"},
{"claim": "If truly uncoupled, RAB29 overexpression would not rescue", "pmid": "30635564"}
]
},
{
"title": "Baseline Elevation from ER Stress Is Epiphenomenon, Not Lysosomal Signal Amplification (H6)",
"description": "G2019S causes elevated baseline RAB10 phosphorylation via chronic ER stress pathway (PERK/eIF2α) unrelated to lysosomal volume-sensing. True signal amplification is pathogenic; baseline elevation is compensatory. PERK inhibitor GSK2606414 can test whether baseline elevation depends on ER stress in both genotypes.",
"target_gene": "PERK,LRRK2",
"dimension_scores": {
"evidence_strength": 0.52,
"novelty": 0.60,
"feasibility": 0.72,
"therapeutic_potential": 0.58,
"mechanistic_plausibility": 0.48,
"druggability": 0.62,
"safety_profile": 0.55,
"competitive_landscape": 0.65,
"data_availability": 0.58,
"reproducibility": 0.58
},
"composite_score": 0.59,
"evidence_for": [
{"claim": "LRRK2 G2019S induces ER stress in dopaminergic neurons", "pmid": "28804131"},
{"claim": "PERK activation affects LRRK2 S935 dephosphorylation", "pmid": "28666988"}
],
"evidence_against": [
{"claim": "PERK activation causes S935 dephosphorylation predicting lower activity, not elevated RAB10-p", "pmid": "28666988"},
{"claim": "ER stress is non-specific—would elevate LRRK2 in WT as well", "pmid": "28666988"}
]
},
{
"title": "Dual-Mechanism Model: G2019S Increases Both Baseline AND Signal-Dependent Phosphorylation (H2)",
"description": "G2019S has two separable effects: (1) increases catalytic efficiency at baseline (higher floor), AND (2) increases LRRK2 membrane affinity upon lysosomal stress, amplifying volume-sensing signals. These may be pharmacologically separable. Membrane-association mutants could distinguish these mechanisms.",
"target_gene": "LRRK2",
"dimension_scores": {
"evidence_strength": 0.55,
"novelty": 0.58,
"feasibility": 0.48,
"therapeutic_potential": 0.65,
"mechanistic_plausibility": 0.50,
"druggability": 0.42,
"safety_profile": 0.60,
"competitive_landscape": 0.68,
"data_availability": 0.52,
"reproducibility": 0.52
},
"composite_score": 0.55,
"evidence_for": [
{"claim": "Cryo-EM structures show G2019S widens the activation segment", "pmid": "31511666"},
{"claim": "G2019S increases both cytosolic and membrane-bound LRRK2 activity", "pmid": "34242571"}
],
"evidence_against": [
{"claim": "Activation segment widening affects catalytic function, not membrane affinity", "pmid": "31511666"},
{"claim": "Membrane-association mutants may disrupt other interactions", "pmid": "34242571"}
]
},
{
"title": "G2019S Amplifies Lysosomal Volume-Sensing Through Membrane Microdomain Partitioning (H5)",
"description": "G2019S increases LRRK2 affinity for negatively charged, curved membranes (PI4P-enriched lysosomal membranes during swelling). This is not a kinase catalytic change but a localization change that amplifies local RAB10 phosphorylation. dSTORM microscopy can quantify membrane density differences between G2019S and WT.",
"target_gene": "LRRK2,PI4P",
"dimension_scores": {
"evidence_strength": 0.45,
"novelty": 0.68,
"feasibility": 0.70,
"therapeutic_potential": 0.52,
"mechanistic_plausibility": 0.40,
"druggability": 0.48,
"safety_profile": 0.58,
"competitive_landscape": 0.72,
"data_availability": 0.52,
"reproducibility": 0.50
},
"composite_score": 0.56,
"evidence_for": [
{"claim": "LRRK2 membrane localization requires PI4P", "pmid": "35189339"},
{"claim": "Lysosomal swelling increases PI4P on limiting membrane", "pmid": "34242571"},
{"claim": "G2019S accelerates LRRK2 autophosphorylation on S1292 (membrane-associated site)", "pmid": "25485852"}
],
"evidence_against": [
{"claim": "G2019S is in kinase domain—structural mechanism for membrane affinity change unexplained", "pmid": "31511666"},
{"claim": "S1292 evidence is indirect marker of membrane association, not direct mechanism", "pmid": "25485852"}
]
}
],
"knowledge_edges": [
{"source_id": "H1", "source_type": "hypothesis", "target_id": "LRRK2", "target_type": "gene", "relation": "mutation causes gain-of-function at lysosomes"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "RAB29", "target_type": "gene", "relation": "recruits hyperactive LRRK2 to stressed lysosomes"},
{"source_id": "H1", "source_type": "hypothesis", "target_id": "RAB10", "target_type": "gene", "relation": "hyperphosphorylated downstream substrate"},
{"source_id": "H2", "source_type": "hypothesis", "target_id": "LRRK2", "target_type": "gene", "relation": "dual catalytic and membrane-affinity effects"},
{"source_id": "H3", "source_type": "hypothesis", "target_id": "LRRK2", "target_type": "gene", "relation": "partial inhibition therapeutic strategy"},
{"source_id": "H4", "source_type": "hypothesis", "target_id": "RAB29", "target_type": "gene", "relation": "critical gatekeeper for amplification"},
{"source_id": "H4", "source_type": "hypothesis", "target_id": "LRRK2", "target_type": "gene", "relation": "amplified signaling requires RAB29 presence"},
{"source_id": "H5", "source_type": "hypothesis", "target_id": "LRRK2", "target_type": "gene", "relation": "altered membrane partitioning mechanism"},
{"source_id": "H5", "source_type": "hypothesis", "target_id": "PI4P", "target_type": "lipid", "relation": "increased affinity during swelling"},
{"source_id": "H6", "source_type": "hypothesis", "target_id": "PERK", "target_type": "kinase", "relation": "ER stress upstream of baseline elevation"},
{"source_id": "H6", "source_type": "hypothesis", "target_id": "LRRK2", "target_type": "gene", "relation": "elevated baseline from ER stress"},
{"source_id": "H7", "source_type": "hypothesis", "target_id": "LRRK2", "target_type": "gene", "relation": "uncoupled from RAB29 spatial control"},
{"source_id": "H7", "source_type": "hypothesis", "target_id": "RAB29", "target_type": "gene", "relation": "binding interface preserved but not functionally coupled"}
],
"synthesis_summary": "The debate reveals that the signal amplification vs. baseline elevation distinction carries profound therapeutic implications: if amplification drives pathology (H3), partial LRRK2 inhibition preserves safety margins while normalizing pathogenic stress responses; if baseline elevation alone is pathogenic, complete inhibition becomes necessary. Current clinical trials (Denali DNL151/BIIB122, Pfizer) are implicitly testing the H3 model but lack mechanistic biomarker stratification to distinguish outcome predictions. The prioritized experimental pathway is: (1) live-cell kinetic imaging (H1) to definitively distinguish amplification from floor effects using fluorescent RAB10 phosphorylation reporters and nigericin-induced swelling—identical rise slopes with baseline offset falsify amplification; (2) CRISPR RAB29 knockout in G2019S iPSC-derived neurons (H4) to determine if amplification requires RAB29, with RAB29 expression as a potential companion diagnostic; (3) embedded mechanistic biomarker studies in ongoing Phase II trials measuring both steady-state and ex-vivo stress-elicited RAB10-p. The membrane partitioning hypothesis (H5) is mechanistically weakest because G2019S resides in the kinase domain, not membrane-targeting regions, and the ER stress hypothesis (H6) fails to explain G2019S specificity given PERK's dephosphorylation effect would predict lower, not higher, activity."
}
```